Overview
SPRC market data
Price History
SPRC price chart · 1M
- O
- 6.81
- H
- 6.81
- L
- 6.81
- C
- 6.81
- Vol
- 0.000000
- Source
- US equities market feed
- Observed
- Aug 21, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $6.81
- Previous Close
- $6.81
- Day High
- $6.81
- Day Low
- $6.81
- 52 Week High
- $15.30
- 52 Week Low
- $3.06
- 7 Day Return
- +3.18%
- 30 Day Return
- +36.20%
- 90 Day Return
- +11.46%
- 1 Year Return
- +57.60%
- Daily Notional Volume
- $0 Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$299.98 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.53 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -1,633.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.98 – $80.10 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $3.8M · P/B 1.05 · P/S 2.91.
Company News
SciSparc Adds Prof. Carmel Domshlak To Newly Established Scientific Advisory Board For AI And Cybersecurity, Effective September 1Benzinga · Aug 26, 2026, 12:37 PM
SciSparc Unit Neurothera Labs And Clearmind Medicine Publish U.S. Patent Application For A Novel Combination Of 3,4-Methylenedioxymethamphetamine And N-Acylethanolamines For Use In Methods Of Treating Post-Traumatic Stress Disorder, Anxiety And Eating DisordersBenzinga · Aug 24, 2026, 1:28 PM
SciSparc shares are trading higher. The company announced its majority-owned subsidiary, NeuroThera Labs, has completed two tranches of non-brokered private placements, raising aggregate gross proceeds of C$5.4 million.Benzinga · Aug 18, 2026, 5:07 PM
SciSparc Invests C$2.7 Million In NeuroThera Financing, Raising Stake To 44.6% Valued At ~C$30 MillionBenzinga · Aug 18, 2026, 12:09 PM
SciSparc Unit Neurothera Labs Receives Japanese Patent For Its Pharmacological Combination Titled 'Compositions And Methods For Potentiating Derivatives Of 4-Aminophenols'Benzinga · Aug 12, 2026, 12:26 PM
SciSparc's NeuroThera Labs Initiates Phase IIb Clinical Study To Evaluate SCI-110 Drug Candidate To Treat Tourette SyndromeBenzinga · Aug 5, 2026, 12:23 PM
What's Going On With SciSparc Shares On Friday?Benzinga · Jul 31, 2026, 2:22 PM
SciSparc Says Majority-Owned Subsidiary NeuroThera Achieved End-To-End Hybrid Quantum-Classical Workflow Milestone For Clinical Trial Data Analytics Platform, Executed In Simulation EnvironmentBenzinga · Jul 31, 2026, 12:21 PM
SciSparc shares are trading higher. The company announced its NeuroThera has completed internal validation of a proprietary quantum sampling workflow developed platform for clinical trials data analysis.Benzinga · Jul 29, 2026, 2:04 PM
SciSparc's NeuroThera Labs Subsidiary Completes Internal Validation Of Quantum Sampling Workflow Developed Platform For Clinical Trials Data AnalysisBenzinga · Jul 29, 2026, 12:35 PM